A novel vaccine platform using glucan particles for induction of protective responses against<i>Francisella tularensis</i>and other pathogens

Abraham, Ambily; Ostroff, Gary R.; Levitz, Stuart M.; Oyston, Petra C. F.

doi:10.1111/cei.13356

Cited by 20 publications

(14 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…β-Glucan Particles β-Glucan particles (GPs) are the most studied vaccine carriers in the β-glucan family. They were developed in 1980s but only widely used as vaccine carriers in recent years (Hunter et al, 2002;Mirza et al, 2017;Abraham et al, 2019). GPs are highly purified, hollow porous cell wall shells with 2-4 µm sizes.…”

Section: β-Glucansmentioning

confidence: 99%

Carbohydrate Conjugates in Vaccine Developments

Lang

Huang

2020

Front. Chem.

View full text Add to dashboard Cite

Vaccines are powerful tools that can activate the immune system for protection against various diseases. As carbohydrates can play important roles in immune recognition, they have been widely applied in vaccine development. Carbohydrate antigens have been investigated in vaccines against various pathogenic microbes and cancer. Polysaccharides such as dextran and β-glucan can serve as smart vaccine carriers for efficient antigen delivery to immune cells. Some glycolipids, such as galactosylceramide and monophosphoryl lipid A, are strong immune stimulators, which have been studied as vaccine adjuvants. In this review, we focus on the current advances in applying carbohydrates as vaccine delivery carriers and adjuvants. We will discuss the examples that involve chemical modifications of the carbohydrates for effective antigen delivery, as well as covalent antigen-carbohydrate conjugates for enhanced immune responses.

show abstract

Section: β-Glucansmentioning

confidence: 99%

Carbohydrate Conjugates in Vaccine Developments

Lang

Huang

2020

Front. Chem.

View full text Add to dashboard Cite

show abstract

“…According to current scientific knowledge, mushroom β-glucans, especially triple-helix β-glucans, represent a promising therapeutic way in anti-tumor therapy due to low side effects [ 85 ], in allergy therapy [ 85 ] and others, like wound healing therapy [ 27 ]. Furthermore, beta-glucans can be used in vaccines [ 86 ] and in nanotechnology and microencapsulation [ 87 ]. Moreover, the most recent research shows that β-glucan extracts from edible mushrooms have coronavirus disease (COVID-19) alleviating properties by reduction of pro-inflammatory cytokines and oxidative stress [ 88 ].…”

Section: Resultsmentioning

confidence: 99%

Evaluation of Polish Wild Mushrooms as Beta-Glucan Sources

Mirończuk-Chodakowska

Witkowska

2020

IJERPH

View full text Add to dashboard Cite

Mushroom beta-glucans show immunomodulatory, anticancer and antioxidant features. Numerous papers have been published in the last years on fungal polysaccharides, especially beta-glucans, demonstrating their various biological activities. However substantial data about beta-glucan contents in many mushroom species, especially wild mushrooms, are still missing. Therefore, the main objective of the study was to evaluate β-glucans in 18 species of wild mushrooms and three species of commercial mushrooms for comparison purposes. The contents of β-glucans were determined by the Megazyme method and with the Congo red method, which differ in analytical procedure. Among wild mushrooms, the highest mean β-glucan content assessed with the Megazyme method was found in Tricholoma portentosum (34.97 g/100 g DM), whereas with the Congo red method in Lactarius deliciosus (17.11 g/100 g DM) and Suillus grevillei (16.97 g/100 g DM). The β-glucans in wild mushrooms assessed with the Megazyme method were comparable to commercial mushrooms, whereas β-glucans assessed with the Congo red method were generally higher in wild mushrooms, especially in Russula vinosa, L. deliciosus and S. grevillei. This study indicates wild mushrooms as interesting material for β-glucan extraction for food industry and medicinal purposes.

show abstract

“…In order to optimal immune response production carrier molecules or adjuvants are required. Indeed, to induce a better immune response, reduce preparation cost and vaccine dose, for improving the efficiency and efficacy of vaccine, adjuvants, and delivery systems are applied [ [1] , [2] , [3] , [4] , [5] ]. Adjuvants through augmenting the immunogenicity of weaker immunogens, increase the effect of the vaccine, and reduce antigen amount and required immunization frequency for protective immunity [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Chitosan, alginate, hyaluronic acid, gums, and β-glucan as potent adjuvants and vaccine delivery systems for viral threats including SARS-CoV-2: A review

Mallakpour

Azadi

Hussain

2021

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Pathogen transmission is a widespread threat to global human health. Vaccines are very important during the outbreak of a pandemic. Destructive fractures caused by a sudden outbreak of COVID-19 have spurred vaccine production at an unprecedented rate. The strategy of an effective vaccine delivery system is opening up novel probabilities to make more immunization. Indeed, vaccination is the most successful way to prevent deaths from infectious diseases. In order to optimal immune response production or improvement in the effectiveness of vaccines, delivery systems or adjuvants are required. Natural polymers such as chitosan, alginate, hyaluronic acid, gums, and β-glucan with antiviral activity have good potential as adjuvant or delivery systems for vaccine formulation development and design vaccine delivery devices. According to the antiviral performance and immunomodulation of these biopolymers, they will play significant characters in the anti-COVID-19 field. In this mini-review, the recent progress in vaccine development by using biopolymers is presented which, provides a reference for their research on anti-COVID-19 drugs and vaccines.

show abstract

A novel vaccine platform using glucan particles for induction of protective responses againstFrancisella tularensisand other pathogens

Cited by 20 publications

References 72 publications

Carbohydrate Conjugates in Vaccine Developments

Carbohydrate Conjugates in Vaccine Developments

Evaluation of Polish Wild Mushrooms as Beta-Glucan Sources

Chitosan, alginate, hyaluronic acid, gums, and β-glucan as potent adjuvants and vaccine delivery systems for viral threats including SARS-CoV-2: A review

Contact Info

Product

Resources

About